Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

The initial report of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group trial E1900 (#NCT00049517) showed that induction therapy with high-dose (HD) daunorubicin (90 mg/m(2)) improved overall survival in adults <60 years old with acute myel...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood
Autores principales: Luskin, Marlise R., Lee, Ju-Whei, Fernandez, Hugo F., Abdel-Wahab, Omar, Bennett, John M., Ketterling, Rhett P., Lazarus, Hillard M., Levine, Ross L., Litzow, Mark R., Paietta, Elisabeth M., Patel, Jay P., Racevskis, Janis, Rowe, Jacob M., Tallman, Martin S., Sun, Zhuoxin, Luger, Selina M.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2016
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4807422/
https://ncbi.nlm.nih.gov/pubmed/26755712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-07-657403
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares